

Application No.: 09/311,162

Page 2

89. (New) The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of SAKELR (SEQ ID NO.: 8), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the SAKELR (SEQ ID NO.: 8).

90. (New) The polypeptide of claim 1, wherein the IL-8 fragment comprises the amino acid sequence AVLPRSAKELR (SEQ ID NO.: 9).

91. (New) The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of AVLPRSAKELR (SEQ ID NO.: 9), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the AVLPRSAKELR (SEQ ID NO.: 9).

92. (New) A composition comprising the polypeptide of claim 88, 89, 90 or 91 and a pharmaceutically acceptable carrier.

93. (New) The polypeptide of claim 88, 89, 90 or 91, wherein the polypeptide is a cyclic polypeptide.

In accordance with the requirements of 37 C.F.R. § 1.121, a marked up version showing the changes to the claims, is attached herewith as Appendix A. For the Examiner's convenience, a complete claim set of the currently pending claims is also submitted herewith as Appendix B.

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with any objection or rejection of record.

REMARKS

The Status of the Claims.

Claims 1, 3, 4, 6-8, 19, and 87-93 are pending with entry of this amendment, claims 88-93 being added herein. These amendments introduce no new matter and support is replete throughout the specification.

With respect to claim 88, support for the IL-8 fragment comprising the amino acid sequence SAKELR (SEQ ID NO.: 8) can be found throughout the specification. For example, see specification at page 27, lines 12-21. With respect to claim 89, support for the IL-8 fragment comprising an amino acid sequence variant of SAKELR (SEQ ID NO.: 8), where the amino acid